Ciprofloxacin in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): A Population Pharmacokinetic Study

Extracorporeal membrane oxygenation (ECMO) is utilized to temporarily sustain respiratory and/or cardiac function in critically ill patients. Ciprofloxacin is used to treat nosocomial infections, but data describing the effect of ECMO on its pharmacokinetics is lacking. Therefore, a prospective, observational trial including critically ill adults (n = 17), treated with ciprofloxacin (400 mg 8–12 hourly) during ECMO, was performed. Serial blood samples were collected to determine ciprofloxacin concentrations to assess their pharmacokinetics. The pharmacometric modeling was performed (NONMEM®) and utilized for simulations to evaluate the probability of target attainment (PTA) to achieve an AUC0–24/MIC of 125 mg·h/L for ciprofloxacin. A two-compartment model most adequately described the concentration-time data of ciprofloxacin. Significant covariates on ciprofloxacin clearance (CL) were plasma bicarbonate and the estimated glomerular filtration rate (eGFR). For pathogens with an MIC of ≤0.25 mg/L, a PTA of ≥90% was attained. However, for pathogens with an MIC of ≥0.5 mg/L, plasma bicarbonate ≥ 22 mmol/L or eGFR ≥ 10 mL/min PTA decreased below 90%, steadily declining to 7.3% (plasma bicarbonate 39 mmol/L) and 21.4% (eGFR 150 mL/min), respectively. To reach PTAs of ≥90% for pathogens with MICs ≥ 0.5 mg/L, optimized dosing regimens may be required.

[1]  H. Endeman,et al.  Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients , 2020, European Journal of Clinical Pharmacology.

[2]  S. Wicha,et al.  Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique , 2020, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  S. Wicha,et al.  Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing , 2020, Frontiers in Pharmacology.

[4]  U. Fuhr,et al.  Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose , 2018, The Journal of antimicrobial chemotherapy.

[5]  J. Fraser,et al.  Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. , 2017, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[6]  G. Grasselli,et al.  Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. , 2017, International journal of antimicrobial agents.

[7]  F. Pea,et al.  Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function , 2016, Antimicrobial Agents and Chemotherapy.

[8]  J. Fraser,et al.  Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study , 2015, Critical Care.

[9]  R J Keizer,et al.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.

[10]  J. Heidelbaugh,et al.  The perils of prescribing fluoroquinolones. , 2013, The Journal of family practice.

[11]  J. Fraser,et al.  Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. , 2012, Journal of critical care.

[12]  Kiran Shekar,et al.  ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO , 2012, BMC Anesthesiology.

[13]  Kiran Shekar,et al.  Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation , 2012, Critical Care.

[14]  J. Fraser,et al.  ECMO – the clinician’s view , 2012 .

[15]  P. Toutain,et al.  Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. , 2011, The Journal of antimicrobial chemotherapy.

[16]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[17]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .

[18]  R. Ariano,et al.  Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. , 2010, The Journal of antimicrobial chemotherapy.

[19]  Sandeep Jain,et al.  Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects , 2010, Journal of enzyme inhibition and medicinal chemistry.

[20]  R. Savic,et al.  Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.

[21]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[22]  J. Roberts,et al.  Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.

[23]  G. Houin,et al.  Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. , 2008, International journal of antimicrobial agents.

[24]  D. Paterson,et al.  Antibiotic resistance—What’s dosing got to do with it? , 2008, Critical care medicine.

[25]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.

[26]  Xh Huang,et al.  Pharmacokinetic-Pharmacodynamic Modeling and Simulation. , 2007 .

[27]  D. Grasela,et al.  Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections , 2001 .

[28]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[29]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[30]  J. Scribante,et al.  Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis , 1998, Antimicrobial Agents and Chemotherapy.

[31]  O. Cars,et al.  Pharmacokinetics and pharmacodynamics of fluoroquinolones. , 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  K. Torniainen,et al.  The effect of pH, buffer type and drug concentration on the photodegradation of ciprofloxacin , 1996 .

[33]  J. Lettieri,et al.  Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects , 1995, Antimicrobial agents and chemotherapy.

[34]  M. Cruciani,et al.  The fluoroquinolones as treatment for infections caused by gram-positive bacteria. , 1994, The Journal of antimicrobial chemotherapy.

[35]  Jerome J. Schentag,et al.  Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin , 1993, Antimicrobial Agents and Chemotherapy.

[36]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[37]  J. Rotschafer,et al.  Clinical Pharmacokinetics of Ciprofloxacin , 1990, Clinical pharmacokinetics.

[38]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .